MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab

MacroGenics reported positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer, with a confirmed objective response rate of 25% and a disease control rate of 44% among 16 evaluable patients. The company described the safety profile as manageable and is enrolling 20 additional patients at 3 mg/kg every three weeks. Updated results are expected in the first half of 2027.